Ep 3: Rise of the Phoenix | Sujal Shah & CymaBay Therapeutics episode artwork

EPISODE · Mar 11, 2025 · 2H 20M

Ep 3: Rise of the Phoenix | Sujal Shah & CymaBay Therapeutics

from Drug Dealin · host Drug Dealin Pod

A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity. Questions?: [email protected] Follow us on X: https://x.com/DrugDealinPodConnect with Shivu: https://linktr.ee/shivusharmaCheck out Big Pharma Sharma: https://bigpharmasharma.substack.com/ Connect with Kenny: https://www.linkedin.com/in/kennylalwani/ Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.00:00 Introduction to Biotech Leadership 03:00 Sujal Shah's Journey in Biotech05:46 Leadership Philosophy and Team Dynamics 09:13 Navigating Challenges at CymaBay 11:48 The Development of seladelpar 15:07 Strategic Decisions in Drug Development 17:58 Clinical Trials and Regulatory Interactions 20:50 The NASH Study and Its Implications 47:10 Navigating Drug Development Challenges 49:07 The Patient-Centric Approach in Drug Development 51:56 Facing Clinical Setbacks and Organizational Resilience 53:36 Unexpected Findings and Immediate Reactions 01:00:27 The Emotional Toll of Drug Development 01:05:08 Rebuilding Purpose and Finding Answers 01:19:52 Patient Advocacy and Support During Crisis 01:23:30 Uncovering the Truth: The Role of Independent Panels 01:33:59 Independent Review and Safety Assurance 01:36:50 Leadership Challenges and Stakeholder Management 01:40:12 Resilience in Adversity 01:43:51 Turning Point: Stock Recovery and Investor Relations 01:47:07 Skepticism and Ongoing Challenges 01:55:00 Data Presentation and Competitive Landscape 02:01:11 Building a Robust Evidence Package 02:04:53 Reflections on Leadership and Future Aspirations

A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity. Questions?: [email protected] Follow us on X: https://x.com/DrugDealinPodConnect with Shivu: https://linktr.ee/shivusharmaCheck out Big Pharma Sharma: https://bigpharmasharma.substack.com/ Connect with Kenny: https://www.linkedin.com/in/kennylalwani/ Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.00:00 Introduction to Biotech Leadership 03:00 Sujal Shah's Journey in Biotech05:46 Leadership Philosophy and Team Dynamics 09:13 Navigating Challenges at CymaBay 11:48 The Development of seladelpar 15:07 Strategic Decisions in Drug Development 17:58 Clinical Trials and Regulatory Interactions 20:50 The NASH Study and Its Implications 47:10 Navigating Drug Development Challenges 49:07 The Patient-Centric Approach in Drug Development 51:56 Facing Clinical Setbacks and Organizational Resilience 53:36 Unexpected Findings and Immediate Reactions 01:00:27 The Emotional Toll of Drug Development 01:05:08 Rebuilding Purpose and Finding Answers 01:19:52 Patient Advocacy and Support During Crisis 01:23:30 Uncovering the Truth: The Role of Independent Panels 01:33:59 Independent Review and Safety Assurance 01:36:50 Leadership Challenges and Stakeholder Management 01:40:12 Resilience in Adversity 01:43:51 Turning Point: Stock Recovery and Investor Relations 01:47:07 Skepticism and Ongoing Challenges 01:55:00 Data Presentation and Competitive Landscape 02:01:11 Building a Robust Evidence Package 02:04:53 Reflections on Leadership and Future Aspirations

NOW PLAYING

Ep 3: Rise of the Phoenix | Sujal Shah & CymaBay Therapeutics

0:00 2:20:49

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Drug Dealin?

This episode is 2 hours and 20 minutes long.

When was this Drug Dealin episode published?

This episode was published on March 11, 2025.

What is this episode about?

A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity. Questions?: [email protected] Follow us on X:...

Can I download this Drug Dealin episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!